申请人:Glaxo Group Limited
公开号:US04918080A1
公开(公告)日:1990-04-17
The present invention provides ketones of the general formula (I): ##STR1## and physiologically acceptable salts and solvates thereof, wherein R.sup.1 and R.sup.2, which may be the same or different, each represents a hydrogen atom or a C.sub.1-6 alkyl group; Im represents an imidazolyl group of formula: ##STR2## wherein one of the groups represented by R.sup.3, R.sup.4 and R.sup.5 is a hydrogen atom or a C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-6 alkenyl, phenyl or phenyl C.sub.1-3 alkyl group, and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C.sub.1-6 alkyl group; and an aromatic or heteroaromatic group as defined in the specification. The compounds are potent and selective antagonists of the effect of 5-HT at 5-HT.sub.3 receptors and are useful, for example, in the treatment of psychotic disorders, anxiety and nausea and vomiting.
本发明提供一般式(I)的酮类化合物:##STR1## 以及其生理上可接受的盐和溶剂物,其中R.sup.1和R.sup.2可以相同也可以不同,分别代表氢原子或C.sub.1-6烷基;Im代表式子的咪唑基:##STR2## 其中由R.sup.3、R.sup.4和R.sup.5代表的其中一个是氢原子或C.sub.1-6烷基,C.sub.3-7环烷基,C.sub.3-6烯基,苯基或苯基C.sub.1-3烷基,而另外两个可能相同也可能不同的基团分别代表氢原子或C.sub.1-6烷基;以及在说明书中定义的芳香族或杂环芳香族基团。这些化合物是5-HT.sub.3受体上5-HT效应的有效和选择性拮抗剂,例如在治疗精神障碍、焦虑和恶心呕吐方面有用。